Q32 Bio Stock (NASDAQ:QTTB)

Forecast Financials Chart

Previous Close

$3.34

52W Range

$3.02 - $53.79

50D Avg

$33.83

200D Avg

$30.59

Market Cap

$43.73M

Avg Vol (3M)

$265.10K

Beta

Div Yield

QTTB Company Profile

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Mar 28, 2018

Website

QTTB Performance

QTTB Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$1.16M	$6.65M	$33.97M
Operating Income	$-92.10M	$-39.23M	$-36.69M
Net Income	$-112.96M	$-42.81M	$-37.56M
EBITDA	$-91.52M	$-36.45M	$-36.65M
Basic EPS	$-35.16	$-0.20	$-0.17
Diluted EPS	$-35.16	$-0.20	$-0.17

Fiscal year ends in Dec 23 | Currency in USD